Planview Announces Strategic Acquisitions of Clarizen and Changepoint to Accelerate Strategy to Delivery for Enterprises
12.1.2021 20:00:00 EET | Business Wire | Press release
Planview, a global leader in Portfolio Management and Work Management, today announced the company has entered into definitive agreements to acquire Clarizen and Changepoint, leading enterprise Project Portfolio Management (PPM) providers.
Across industries, enterprises are transforming their businesses to be digital-first. This shift has only accelerated during the COVID-19 pandemic, and what’s emerged is a new and enduring way of working that’s flexible, highly distributed, and digital. As increasingly dispersed teams embrace new tools and processes to meet the evolving needs of their customers, visibility and connectivity across the enterprise have never been more critical. The market demands a comprehensive software platform that can connect strategy to delivery across siloed workstreams and disciplines – capabilities best provided through PPM and Agile.
The combination of Planview, Clarizen, and Changepoint creates a unique platform enabling organizations to better collaborate, deliver, and thrive in this new world of work. Backed by TPG Capital and TA Associates, the combination harnesses the capabilities of three leading providers to deliver customers an unmatched level of expertise, IP, and resources to ensure their most important outcomes are delivered with efficiency, urgency, and transparency.
“In today’s environment, enterprises are looking for partners with the vision, expertise, and scale to help them navigate and excel in our all-digital world,” said Greg Gilmore, CEO of Planview. “Planview, Clarizen, and Changepoint are all leaders, and together, our customers create an exceptional community of PMOs, PPM and Professional Services Automation (PSA) practitioners. Collectively, there is no better platform to drive innovation and fuel the transformation of strategy to delivery.”
Since inception, Planview has focused on partnering with enterprises to help them re-imagine the ways they plan and manage work. With Clarizen and Changepoint’s leadership and category expertise, Planview will provide customers of all sizes with a robust community and end-to-end offering that enables them to meet their unique business goals and drive better business outcomes. In addition to leading Enterprise Agile Planning and Kanban from Planview, Clarizen and Changepoint customers will benefit from the expanded resources that Planview delivers.
“We’re thrilled to be joining forces with two organizations that share our core belief of putting customers at the heart of everything we do,” said Matt Zilli, CEO of Clarizen. “By bringing together these companies, customers will have access to a portfolio of industry leading solutions from three world-class companies, as well as new innovation as we focus on providing even more value to our customers.”
“In order to achieve meaningful business outcomes, organizations need to be adaptable and nimble while ensuring alignment from strategic planning to delivery,” said Matt Scheuing, CEO of Changepoint. “We look forward to working with the Planview and Clarizen teams and believe the combination of exceptional Portfolio and Work Management solutions, practitioners and experts will enable our customers to continue to succeed in an ever-changing business environment.”
Upon completion of the transactions, the Clarizen and Changepoint teams will join Planview as distinct business units, led by Matt Zilli and Matt Scheuing. Zilli and Scheuing will report into Planview CEO, Greg Gilmore. The transaction is expected to close in the first quarter of 2021. Terms of the transaction were not disclosed. To learn more, visit Planview.com.
About Planview
Planview has one focus: enabling the transformation journey as organizations rewire strategy to delivery in today’s fast-paced, highly disruptive markets. Our solutions enable organizations to navigate this journey and accelerate on-strategy delivery at enterprise scale. Planview’s full spectrum of Portfolio Management and Work Management solutions create organizational focus on the strategic outcomes that matter and empower teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enable customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, Planview has more than 700 employees supporting 3,500 customers and 1 million users worldwide. For more information, visit: www.planview.com.
About Clarizen
Clarizen connects work across the enterprise, turning ideas into strategies, plans, and action. With Clarizen, organizations can work the way they want to work and have real time visibility into all their workstreams. This keeps teams focused on the things that matter, delivers results faster, and helps them exceed their company goals and customers’ expectations. Thousands of global customers, such as Jones Lang LaSalle (JLL), Siemens, De Beers, Ricoh, Box and Shaw Industries, across a wide variety of industries in 124 countries rely on Clarizen to help them achieve their business goals. To learn more, visit www.clarizen.com.
About Changepoint
Changepoint transforms project, engagement and application portfolios with an adaptable, intuitive and intelligent platform that is configurable for an agile business. Changepoint’s built-for-purpose portfolio management solutions are designed for strategic transformation leaders, project management offices, services organizations, and IT leaders. Hundreds of global customers partner with us to make informed and innovative business decisions, enable transformation, maximize profit, drive visibility, and align outcomes to strategy. Achieve better business outcomes at www.changepoint.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210112005685/en/
Contact information
Planview
Leslie Marcotte
719-439-4921
lmarcotte@planview.com
Clarizen
Andrew Ryan, Actual Agency
954-495-6786
andrew.ryan@actual.agency
Changepoint
Andy Tolton
425-681-2770
andy.tolton@changepoint.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 12:52:00 EEST | Press release
The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not merely a wage dispute. It stems from deep structural concerns regarding the company’s ESG management, lack of operational autonomy, and passive labor relations. Primarily, the union highlighted unresolved corporate governance issues, including allegations concerning unfair labor practices and the unauthorized use of employee personal data, which were prominently reported by South Korea's major broadcaster, MBC, in November 2025. The union believes this crisis stems from management's failure to address r
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 12:00:00 EEST | Press release
The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that elevates high-performance riders and horses to their rightful place on the world stage. Built on merit, integrity, and excellence, the PJL brings together the world’s best athletes to compete for the biggest prize pot in the discipline’s history, helping to create a more resilient, long-term financial model for the sport. Represented by sixteen teams, the PJL will introduce an industry-first rider selection process from a pool of 250 of the world’s leading riders. World-class, immersive events will unfold across fourteen ic
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 12:00:00 EEST | Press release
Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkbj) for the treatment of spastic cerebral palsy (CP). On top of safety and tolerability, the study will evaluate improvements in daily functioning, quality of life, motor abilities, and neurodevelopmental measures of the Cenegermin-bkbj intranasal formulation. CP is the most common motor disability in childhood, caused by injury or changes during early brain development. The most prevalent form, spastic CP, leads to muscle stiffness and difficulty with movement.2 “Cerebral palsy is a devastating disease, and for patients and families there are still no proven treatments beyond supportive care,” said Marcello Allegretti, Chief Scientific Officer at Dompé. “With our emerging intranasal NGF p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom